search
Back to results

Pleasure for Food and Endocannabinoids in Obesity (PLOBEC)

Primary Purpose

Obesity

Status
Unknown status
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Computer-based tasks
Blood sampling
Sponsored by
Institut National de la Santé Et de la Recherche Médicale, France
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional screening trial for Obesity focused on measuring Obesity, food pleasure, behavioral tasks, endocannabinoids

Eligibility Criteria

18 Years - 60 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

Obese patients :

  1. Be between 18 and 60 year-old
  2. Have a body mass index ranging from 35 to 50 kg/m2
  3. Have no previous history of surgical treatment of obesity
  4. Have received no standard intervention for obesity within the last 3 months before study
  5. Have a stable weight (variation <5%) within the last 3 months before study
  6. Have a restriction score <9 on the three-factor eating questionnaire
  7. Be free from any current and previous psychiatric disorder, such as major depression or drug abuse/dependence
  8. Understand and accept the design and constraints of the present study
  9. Be a beneficiary or member of health insurance plan
  10. Provide written consent to the study after receiving clear information

Healthy volunteers :

  1. Be between 18 and 60 year-old
  2. Be free from any current and previous psychiatric disorder, such as major depression or drug abuse/dependence
  3. Understand and accept the design and constraints of the present study
  4. Be a beneficiary or member of health insurance plan
  5. Provide written consent to the study after receiving clear information

Exclusion Criteria:

Obese patients :

  1. Suffer from monogenic obesity
  2. Take any psychotropic treatment such as anxiolytic/hypnotic drugs over the last week preceding the study
  3. Be a pregnant or nursing woman
  4. Use alcohol over the last two days preceding the study

Healthy volunteers :

  1. Suffer from any current and previous somatic or psychiatric condition
  2. Have a body mass index below 18,5 kg/m2 or above 25 kg/m2
  3. Take any psychotropic treatment such as anxiolytic/hypnotic drugs over the last week preceding the study
  4. Be a pregnant or nursing woman
  5. Use alcohol over the last two days preceding the study

Sites / Locations

  • Neurocentre Magendie (INSERM U862)Recruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Obese patients

Normal-weight healthy volunteers

Arm Description

Computer-based tasks evaluating size and time discrimination capacities Blood sampling for the determination of plasma endocannabinoids levels

Computer-based tasks evaluating size and time discrimination capacities Blood sampling for the determination of plasma endocannabinoids levels

Outcomes

Primary Outcome Measures

Change in the Point of subjective equality (PSE)
The PSE is defined as the ratio "F"/"D" or "C"/"D" for which the stimulus "F" or "C" was judged greater than "D" with a probability of 0.5

Secondary Outcome Measures

Change in the Percentage of subjective discrimination (PSD)
The PSD is defined as the percentage of responses where the stimulus "F" or "C" was judged greater than "D" during the trials where the stimulus "F" or "C" was physically equal to "D", in terms of size or duration of presentation.
Circulating endocannabinoids concentrations

Full Information

First Posted
November 4, 2013
Last Updated
February 23, 2016
Sponsor
Institut National de la Santé Et de la Recherche Médicale, France
search

1. Study Identification

Unique Protocol Identification Number
NCT01985139
Brief Title
Pleasure for Food and Endocannabinoids in Obesity
Acronym
PLOBEC
Official Title
A New Method for the Characterisation of Pleasure for Food in Obesity and Relationships With the Endocannabinoid System
Study Type
Interventional

2. Study Status

Record Verification Date
February 2016
Overall Recruitment Status
Unknown status
Study Start Date
January 2014 (undefined)
Primary Completion Date
February 2016 (Anticipated)
Study Completion Date
February 2016 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Institut National de la Santé Et de la Recherche Médicale, France

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Disturbances in hedonic and motivational processes play a major role in the pathophysiology of obesity. To date, experimental approaches for the study of emotional and motivational processing rely on subjective assessment scales. We have therefore developed two novel computer-generated tasks challenging respectively visual and temporal discrimination capacities for a quantitative and objective measurement of the hedonic and motivational state in humans. According to the task, the subjects are asked to view and to compare two stimuli, an appetitive one (food pictures) and its devalued counterpart (food pictures in greyscale), at each trial, assessing either the size (task A) or the duration of presentation (task B). From these considerations, the present project aims at using our novel tool to: i) assess the hedonic and motivational state in subjects with obesity, ii) compare their responses with healthy volunteers, and iii) establish relationships with biological markers known to be highly involved in the regulation of both emotional and motivational processes, such as endocannabinoids. The present project should demonstrate that the behavioral tests validated in our laboratory are relevant experimental tools for the diagnostic/clinical assessment and for the phenotypic characterization of obese patients. The application of the test in the therapeutic context could add further information about the efficacy and relevance of the chosen therapy. Finally, our project will provide information on the biological substrates of hedonic and motivational impairments that might become target of therapy in obesity.
Detailed Description
Disturbances in hedonic and motivational processes play a major role in the pathophysiology of reward-related diseases, such as obesity. To date, experimental approaches for the study of emotional and motivational processing rely on subjective assessment scales. We have therefore developed and validated a novel computer-generated test challenging visual and temporal discrimination capacities in humans. The subjects are asked to view and to compare two stimuli, an appetitive one (food pictures; F) and its devalued counterpart (food pictures in greyscale; D), at each trial, assessing either the size (task A) or the duration of presentation (task B). Geometric figures are used as controls and presented in color (C) or greyscale (D). Both tasks are registered under the French agency for the protection of computer software. Here, we propose to use our novel test to: i) assess the hedonic and motivational state in subjects suffering from obesity, ii) compare their responses with healthy volunteers, and iii) establish relationships with biological markers known to be highly involved in the regulation of both emotional and motivational processes, such as endocannabinoids. Responses to the test in obese patients will be evaluated during two separate experimental sessions under either fasting or satiety conditions. The present study is expected to begin mid-November 2013 for a total duration of 24 consecutive months. A sample of 25 patients suffering from obesity will be recruited and compared with 25 healthy normal volunteers who are free from any previous or current metabolic and psychiatric disorders. They will be matched on age and sex. They will be screened using the "Association pour la Méthodologie et la Documentation en Psychiatrie" questionnaire for obtaining a series of information, comprising the marital status, number of children, number of siblings, education and training, professional qualifications, significant life events… They will be evaluated with the Mini-International Neuropsychiatric Interview in order to determine the presence of mood disorders and associated psychopathology. The Three-Factor Eating Questionnaire will be employed for measuring three separate aspects of eating behavior: cognitive restraint, uncontrolled eating, and emotional eating. This will be completed with the Multidimensional Body Self-Relations Questionnaire and the State-Trait Anxiety Inventory in order to assess the body satisfaction and anxiety levels, respectively. Beyond all these assessments, two separate experimental sessions will be conducted, one in satiety and the other in fasting. During each session, the participants will be asked to perform the two validated instrumental tasks in front the screen of a computer. Plasma levels of endocannabinoids will be monitered by collecting blood samples prior to the consumption of a calorically-defined meal and while carrying out the computer-generated tasks under satiety. Blood will be withdrawn at the same time-points during the session in fasting. Visual analogue scales (VAS) assessing hunger levels will be completed before blood is collected. A VAS will be also used for the global assessment of appetitive properties of the viewed food images just before the end of the second experimental session.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity
Keywords
Obesity, food pleasure, behavioral tasks, endocannabinoids

7. Study Design

Primary Purpose
Screening
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Non-Randomized
Enrollment
50 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Obese patients
Arm Type
Experimental
Arm Description
Computer-based tasks evaluating size and time discrimination capacities Blood sampling for the determination of plasma endocannabinoids levels
Arm Title
Normal-weight healthy volunteers
Arm Type
Experimental
Arm Description
Computer-based tasks evaluating size and time discrimination capacities Blood sampling for the determination of plasma endocannabinoids levels
Intervention Type
Behavioral
Intervention Name(s)
Computer-based tasks
Intervention Description
Computer-based tasks designed to assess size and time discrimination capacities
Intervention Type
Biological
Intervention Name(s)
Blood sampling
Intervention Description
Blood drawn for the measurement of circulating endocannabinoids concentrations
Primary Outcome Measure Information:
Title
Change in the Point of subjective equality (PSE)
Description
The PSE is defined as the ratio "F"/"D" or "C"/"D" for which the stimulus "F" or "C" was judged greater than "D" with a probability of 0.5
Time Frame
From fasting to satiety conditions 3 days apart (days 4 and 7 after inclusion)
Secondary Outcome Measure Information:
Title
Change in the Percentage of subjective discrimination (PSD)
Description
The PSD is defined as the percentage of responses where the stimulus "F" or "C" was judged greater than "D" during the trials where the stimulus "F" or "C" was physically equal to "D", in terms of size or duration of presentation.
Time Frame
From fasting to satiety conditions 3 days apart (days 4 and 7 after inclusion)
Title
Circulating endocannabinoids concentrations
Time Frame
Determined on blood samples collected during the experimental sessions under fasting and satiety (days 4 and 7 after inclusion)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Obese patients : Be between 18 and 60 year-old Have a body mass index ranging from 35 to 50 kg/m2 Have no previous history of surgical treatment of obesity Have received no standard intervention for obesity within the last 3 months before study Have a stable weight (variation <5%) within the last 3 months before study Have a restriction score <9 on the three-factor eating questionnaire Be free from any current and previous psychiatric disorder, such as major depression or drug abuse/dependence Understand and accept the design and constraints of the present study Be a beneficiary or member of health insurance plan Provide written consent to the study after receiving clear information Healthy volunteers : Be between 18 and 60 year-old Be free from any current and previous psychiatric disorder, such as major depression or drug abuse/dependence Understand and accept the design and constraints of the present study Be a beneficiary or member of health insurance plan Provide written consent to the study after receiving clear information Exclusion Criteria: Obese patients : Suffer from monogenic obesity Take any psychotropic treatment such as anxiolytic/hypnotic drugs over the last week preceding the study Be a pregnant or nursing woman Use alcohol over the last two days preceding the study Healthy volunteers : Suffer from any current and previous somatic or psychiatric condition Have a body mass index below 18,5 kg/m2 or above 25 kg/m2 Take any psychotropic treatment such as anxiolytic/hypnotic drugs over the last week preceding the study Be a pregnant or nursing woman Use alcohol over the last two days preceding the study
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Bruno Aouizerate, professor
Phone
05 57 57 37 06
Ext
+33
Email
bruno.aouizerate@u-bordeaux2.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Bruno Aouizerate, Professor
Organizational Affiliation
Neurocentre Magendie (INSERM U862)
Official's Role
Principal Investigator
Facility Information:
Facility Name
Neurocentre Magendie (INSERM U862)
City
Bordeaux
ZIP/Postal Code
33077
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Bruno Aouizerate, Professor
Phone
05 57 57 37 06
Ext
+33
Email
bruno.aouizerate@u-bordeaux2.fr
First Name & Middle Initial & Last Name & Degree
Bruno Aouizerate, Professor
First Name & Middle Initial & Last Name & Degree
Antoine Tabarin, Professor
First Name & Middle Initial & Last Name & Degree
Blandine Gatta-Cherifi, Professor
First Name & Middle Initial & Last Name & Degree
Camille Gouzien, Doctor

12. IPD Sharing Statement

Learn more about this trial

Pleasure for Food and Endocannabinoids in Obesity

We'll reach out to this number within 24 hrs